The press service of the Russian Federal Biomedical Agency announced that clinical trials based on mefloquine, hydroxychloroquine and caledavir drugs for the treatment of patients with coronavirus have started in Russia.
"The clinical trials of hydroxychloroquine and mefloquine and the Russian drug Calidavir have been started, which will be used according to new medical indications for the treatment of patients with the emerging coronavirus infection," the Russian news agency Sputnik quoted the press service as saying.
The press service added that clinical studies will be conducted at the "Burnazian" medical center, based on the written consent of patients with the new Coronavirus.
Earlier, the press service of the Russian Biomedical Agency had announced that it had provided a treatment regimen for the Corona virus on the basis of anti-malarial mefloquine.
The agency suggested to the Russian Ministry of Health to include the treatment system in the plan to combat the Corona virus.